Victoire Cardot-Ruffino, Naima Bollenrucher, Luisa Delius, S Jennifer Wang, Lauren K Brais, Joshua Remland, C Elizabeth Keheler, Keri M Sullivan, Thomas A Abrams, Leah H Biller, Peter C Enzinger, Nadine J McCleary, Anuj K Patel, Douglas A Rubinson, Benjamin Schlechter, Sarah Slater, Matthew B Yurgelun, James M Cleary, Kimberly Perez, Michael Dougan, Kimmie Ng, Brian M Wolpin, Harshabad Singh, Stephanie K Dougan
BACKGROUND: Recombinant granulocyte colony-stimulating factor (G-CSF) is routinely administered for prophylaxis or treatment of chemotherapy-induced neutropenia. Chronic myelopoiesis and granulopoiesis in patients with cancer has been shown to induce immature monocytes and neutrophils that contribute to both systemic and local immunosuppression in the tumor microenvironment. The effect of recombinant G-CSF (pegfilgrastim or filgrastim) on the production of myeloid-derived suppressive cells is unknown...
June 2023: Journal for Immunotherapy of Cancer